Long-term outcome of High-risk Prostate Cancer Treated with Brachytherapy Combined with External-beam Radiation Therapy and Androgen Deprivation Therapy-Reference-Cited by-同舟云学术

Long-term outcome of High-risk Prostate Cancer Treated with Brachytherapy Combined with External-beam Radiation Therapy and Androgen Deprivation Therapy

Published:2014-09 Issue:5 Volume:100 Page:524-528
ISSN:0300-8916
Container-title:Tumori Journal
language:en
Short-container-title:Tumori Journal

Author:

Chen Jian¹,Yan Wei-gang¹,Li Han-zhong¹,Ji Zhi-gang¹,Zhou Yi¹,Zhou Zhi-en¹,Mai Zhi-peng¹

Affiliation:

1. Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China

Publisher

SAGE Publications

Subject

Cancer Research,Oncology,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/1660.18170

Reference31 articles.

1. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience

2. Long-Term Outcome for Clinically Localized Prostate Cancer Treated With Permanent Interstitial Brachytherapy

3. 10-YEAR DISEASE-FREE SURVIVAL RATES AFTER SIMULTANEOUS IRRADIATION FOR PROSTATE CANCER WITH A FOCUS ON CALCULATION METHODOLOGY

4. 12-YEAR OUTCOMES FOLLOWING PERMANENT PROSTATE BRACHYTHERAPY IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER

5. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Significance of androgen‐deprivation therapy for intermediate‐ and high‐risk prostate cancer treated with high‐dose radiotherapy: A literature review;International Journal of Urology;2024-07-17

2. Phase II clinical trial of sequential treatment with systemic chemotherapy and intraperitoneal paclitaxel for gastric and gastroesophageal junction peritoneal carcinomatosis - STOPGAP trial;BMC Cancer;2023-03-04

3. Intraperitoneal infusion of recombinant human endostatin improves prognosis in gastric cancer ascites;Future Oncology;2022-03